{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000046","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.667490+00:00","generated_at":"2026-06-11T02:54:14.744203+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NovoCure's INNOVATE-3 trial fails primary endpoint: no OS benefit in ovarian cancer","bullets":["Median OS 12.2 months (TTFields + paclitaxel) vs 11.9 months (paclitaxel alone); HR 1.008.","540 patients enrolled; trial designed for platinum-resistant ovarian cancer.","TTFields therapy well-tolerated without added systemic toxicities.","Exploratory subgroup suggests potential survival benefit in patients with only one prior therapy line.","Full data analysis ongoing; results to be shared with scientific community."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000046","json":"https://secwatch.observer/filing/0001645113-23-000046.json","markdown":"https://secwatch.observer/filing/0001645113-23-000046.md","text":"https://secwatch.observer/filing/0001645113-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000046/0001645113-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000046/nvcr-20230828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:54:14.744203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}